Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~- Meet renal function criteria in one of four categories~Exclusion Criteria:~- Unstable or uncontrolled medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Normal renal function): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group B (End Stage Renal Disease): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group C (Moderate renal impairment): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1
- Group D (Severe renal impairment): Daclatasvir (Type: EXPERIMENTAL): Daclatasvir 60 mg tablet by mouth single dose on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).